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Abstract 
 
Lipocalins are a family of proteins characterized by a conserved eight-stranded β-barrel 
structure with a ligand binding pocket. They perform a wide range of biological 
functions and this functional multiplicity must relate to the lipid partner involved. 
Apolipoprotein D (ApoD) and its insect homologues, Lazarillo (Laz) and Neural 
Lazarillo (NLaz), share common ancestral functions like longevity, stress resistance and 
lipid metabolism regulation, coexisting with very specialized functions, like courtship 
behavior. Using tryptophan fluorescence titration we screened binding of fifteen 
potential lipid partners for NLaz, ApoD and Laz and uncovered several novel ligands 
with apparent dissociation constants in the low micromolar range. Retinoic acid (RA), 
retinol, fatty acids and sphingomyelin are shared ligands. Sterols however showed a 
species specific binding pattern: Cholesterol did not show strong binding to human 
ApoD, while NLaz and Laz did bind ergosterol. Among the Lipocalin-specific ligands, 
we found that ApoD selectively binds the endocannabinoid anandamide but not 2-
acylglycerol, and that NLaz binds the pheromone 7-tricosene but not 7,11-
heptacosadiene or 11-cis-vaccenyl acetate. To test the functional relevance of Lipocalin 
ligand-binding at the cellular level, we analyzed the effect of ApoD, Laz and NLaz 
preloaded with RA on neuronal differentiation. Our results show that ApoD is necessary 
and sufficient to allow for RA differentiating activity. Both human ApoD and 
Drosophila NLaz successfully deliver RA to immature neurons, driving neurite 
outgrowth. We conclude that ApoD, NLaz and Laz bind selectively to a different but 
overlapping set of lipid ligands. This multispecificity can explain their varied 
physiological functions.
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1. Introduction 
 
Lipocalins are an ancient and functionally diverse family of proteins characterized 
by their ability to bind and transport a variety of ligands, including in some cases 
bioactive lipids. Noted examples of functional lipocalin-lipid associations include (i) 
Retinol Binding Protein (RBP) and retinol [1], (ii) Apolipoprotein M (ApoM) and 
sphingosine-1-phosphate (S1P) [2] and (iii) the enzyme Prostaglandin D Synthase (L-
PGDS) and its substrate prostaglandin-H2 (PGDH2) [3]. Despite limited sequence 
identity, the Lipocalin three-dimensional structure: an eight-stranded antiparallel -
barrel with accessory - and 310 helices, is well conserved through evolution. The 
Lipocalin fold forms a cup, or calyx, with a central cavity, which serves as a ligand-
binding site [4]. 
Apolipoprotein D (ApoD) is an extracellular glycosylated Lipocalin expressed with 
a wide temporal and tissue distribution. Although detected in liver, spleen, skin and 
placenta, ApoD is mostly present in serum and nervous system [reviewed by 5]. Plasma 
ApoD is mainly associated with high-density lipoproteins (HDL), but can also be found 
in very low- and low-density lipoproteins (VLDL, LDL) [6, 7]. ApoD nervous system 
expression has been studied during development [8-10], and it is known to increase 
during prefrontal cortex maturation, a period marked by active lipid metabolism [11]. 
On the other hand, ApoD is the most consistently up-regulated gene during brain aging 
in mammals [12, 13]. ApoD levels are also elevated in many neurodegenerative 
diseases, including Alzheimer’s [14], Parkinson’s [15], schizophrenia [16] and multiple 
sclerosis [17]. In the mouse model of Niemann-Pick type C (NPC) disease [18], caused 
by deficiencies in cholesterol metabolism and management, ApoD expression is also 
up-regulated. 
ApoD is considered the most ancient vertebrate Lipocalin and has homologues in 
many other phyla [19, 20]. Neural Lazarillo (NLaz) from the fruitfly Drosophila 
melanogaster and Lazarillo (Laz) from the grasshopper Schistocerca americana are two 
of the most studied ApoD homologues. Many ApoD, NLaz and Laz functions are 
conserved during evolution, and include protection against oxidative stress, and 
longevity and metabolism regulation [21-27]. Oxidative stress protection has been 
established for ApoD homologues in vivo, and the ApoD molecule itself exhibits anti-
oxidant properties in vitro [28, 29]. The regulation of ApoD and NLaz expression are 
also conserved, as both are controlled by the JNK signaling pathway under stress 
conditions [22, 26]. Furthermore, ApoD and NLaz have been proposed as functional 
links between the nervous system and adipose tissue in both mammals and insects [22, 
30]. 
 
The biochemical mechanism by which ApoD and related Lipocalins perform their 
function is not understood, though their hydrophobic pockets and potential ligands are 
obvious candidates to be explored. The wide range of tissue expression and 
physiological roles of ApoD, NLaz and Laz suggest that particular functions are 
dependent on specific ligands. Thus, determining the ligand specificity of these 
Lipocalins is essential to define their molecular mechanism. 
Several ligands have been described for ApoD, but not without controversy. 
Progesterone-ApoD binding has been documented [31-35] and the complex co-
crystallized [36]. In addition, arachidonic acid (AA) [34, 35], retinol, and retinoic acid 
(RA) [37] are in vitro ApoD ligands. However, a consensus has not been reached on 
whether bilirubin [7, 35], odorants like E-3-methyl-2-hexenoic acid [35, 38] or other 
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steroids, such as cholesterol [34, 39] and pregnenolone [33, 35], are bona fide functional 
ApoD ligands. 
Laz shows positive binding for RA, AA, linoleic acid (LA) and palmitic acid (PA) 
[40]. However, the Drosophila NLaz ligand preferences have not been characterized. 
The aim of this work is to identify new putative lipophilic ligands for the ApoD-
related Lipocalins, which should contribute to understand how they perform their 
physiological functions in different tissues and cellular contexts. Placing these results in 
an evolutionary context will help us distinguish derived versus ancestral protein-lipid 
functional associations. Finally, we assay at the cellular level the effect of ApoD-RA 
binding pair on a particular biological function: the differentiation of neurons in culture. 
 
 
2. Results and Discussion 
 
2.1. Binding properties of ApoD and its related insect homologues. 
 
Intrinsic fluorescence titration was used to characterize the ligand binding 
capacities of ApoD, NLaz and Laz, an approach that has been successfully employed in 
many other Lipocalin binding studies [e.g.: 37, 40]. A panel of 15 small hydrophobic 
molecules was tested, including lipids with different size, shape, chemical properties 
and biological functions. Ligands identified in other studies were also included. 
Previous studies were carried out using proteins recombinantly expressed in E.coli 
[35, 40]. Since the three Lipocalins are glycoproteins, we performed our study with 
their glycosylated forms, avoiding undesired effects on the calyx structure or binding 
properties due to the lack of glycosylation. To perform the binding assays we purified 
the proteins either from native sources (ApoD) or from a eukaryotic expression system 
(NLaz and Laz). 
 
2.1.1. Retinol and retinoic acid: classical Lipocalin ligands. 
 
Retinol and retinoic acid (RA) are common ligands for most Lipocalins, including 
ApoD and Laz [37, 40]. The Lipocalin retinol binding protein (RBP) delivers retinol to 
several target tissues [41], and the physiological relevance of RBP-retinol interaction 
has been reported, for RBP mutations preventing retinol binding cause night blindness 
[42]. 
RA and especially retinol bind to ApoD with high affinity [37]. Our binding studies 
confirm that ApoD tightly binds retinol and RA (Fig. 1A and 1D) with KD values of 0.2 
M for the ApoD-retinol and 4 M for ApoD-RA interactions (Table 1). The higher 
affinity of ApoD for retinol over RA reported here is in agreement with previous results 
[37]. 
A study of bacterially-expressed recombinant grasshopper Laz binding to RA 
reported a KD in the low micromolar range [40]. Here we have confirmed the Laz-RA 
interaction with bacterially-expressed Laz (Fig. S3A), as well as with the glycosylated 
eukaryotic Laz produced by S2 cells (Fig. 1C). Binding to both forms results in similar 
KD (Table 1). Additionally, retinol was evaluated as a Laz ligand with positive results 
(Fig. 1F). RA and retinol have well known critical roles during vertebrate development 
[43]. The recent quantification of RA in locust embryos [44], previously thought to be 
absent in insects, suggests an involvement of Laz-retinol or -RA interactions in the Laz 
known functions during insect development [45]. 
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Binding specificities for retinol and RA were also conserved in NLaz (Fig. 1B and 
1E), with KD values similar to those for ApoD or Laz (Table 1). Taken together, the 
binding of retinol or RA to both NLaz and Laz suggests a putative conserved 
physiological role for ApoD-related Lipocalins in insects, which lack a recognizable 
RBP ortholog [19]. 
To determine whether ApoD, NLaz or Laz binding to RA was dependent on the 
protein tertiary structure, denatured forms of all three Lipocalins were used in parallel 
binding assays, with the result that GuHCl denaturation hinders RA binding to ApoD, 
NLaz and Laz (Fig. S2). We conclude that an intact Lipocalin calyx is required for 
specific binding. 
 
2.1.2. Lipids present in HDL particles and plasma membrane are putative ligands 
for ApoD-related Lipocalins. 
 
ApoD was initially discovered as a component of HDL [46], where it is disulfide-
linked to ApoA-II [47]. This discovery suggested that cholesterol is a potential ApoD 
ligand. Here we find no ApoD-cholesterol interaction in the micromolar range (Fig. 2A) 
in agreement with previous results where no interaction [34] or interaction in the 
millimolar range [39] were found, far from the low micromolar to nanomolar KD values 
typical of physiologically relevant Lipocalin-ligand interactions [48]. Although ApoD is 
not able to bind non-esterified cholesterol with high affinity, many studies have shown a 
relationship between ApoD expression and cholesterol levels in tissues or organisms, or 
have proposed cholesterol binding as a physiological mechanism [e.g.: 49, 50]. For 
example, ApoD is up-regulated in a mouse model of NPC disease [18] where 
cholesterol metabolism is impaired. Also, the addition of ApoD to organotypic 
hippocampal cultures reduced the amount of 7-ketocholesterol (an oxidized from of 
cholesterol) after kainate-induced excitotoxicity [51]. Although these results are 
suggestive of cholesterol binding, the observed correlations between ApoD and 
cholesterol levels cannot be ascribed to a direct cholesterol-ApoD interaction.  
Drosophila cannot synthesize sterols and requires a dietary source. Ergosterol is the 
major sterol in the yeast-based Drosophila food used in laboratories [52]. Interestingly, 
NLaz and Laz can bind ergosterol with KD values of 2 and 2.1 µM respectively (Fig. 
2B-C). This finding differs from that obtained for hApoD-cholesterol interaction, and 
invites to test whether the lipocalin calyces and sterol binding properties are a species-
specific divergent trait. Although the interaction might not be physiologically relevant, 
we tested ergosterol binding to ApoD, and cholesterol binding to NLaz and Laz. ApoD 
does not bind ergosterol (Fig. S4-A). Cholesterol binding is observed for NLaz, but not 
for Laz (Fig. S4-B and C). These results reveal structural dissimilarities among the three 
ligand binding pockets (see Fig. 7) and shows that ApoD binding cavity does not have 
properties compatible with binding to these sterols in the concentration range studied. 
 
Sphingomyelin (SM) is the major sphingolipid in HDL particles and plasma 
membranes. SM has high affinity for cholesterol, and both lipids pack tightly forming 
lipid rafts and caveolae [53]. SM also regulates cholesterol efflux from cellular 
membranes to HDL via the ATP-binding cassette transporter A1 (ABCA1) [54]. A 
connection of ApoD with SM is supported by the enrichment in SM of ApoD-
containing blood lipoparticles [6], and by the role played by ApoD in maintaining 
peripheral nerve myelin sheath [55], a cell compartment that contains a high 
concentration of SM. Here we find that ApoD and the related insect Lipocalins NLaz 
and Laz bind palmitoyl-SM (Fig. 2D-F) with KD values of 1.3 µM (ApoD), 4.6 µM 
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(NLaz) and 2.7 µM (Laz). The Laz-SM interaction has a similar KD value when using 
the bacterially-expressed form of Laz (Fig. S3B). Thus, SM is a common ligand for this 
group of Lipocalins, with ApoD exhibiting a higher affinity for SM than NLaz or Laz 
(Table 1). The number of carbons in the sphingoid base differ across species [53] and 
could potentially explain the differential affinities observed. Here, we used SM with a 
C18:1 sphingoid base, one of the typical forms found in humans, whereas C14:0 and 
C14:1 are the major sphingoid base isoforms in insects [53]. 
Since this is the first report of binding of SM to any Lipocalin, and SM binding is 
conserved for ApoD, NLaz and Laz, SM could be a ligand for other Lipocalins. We 
tested SM binding to α1-microglobulin (α1-mg), a Lipocalin more distantly related to 
the ApoD group [19]. No binding interaction was detected for α1-mg and SM (Fig. 
S3D), demonstrating the specificity of this assay and suggesting that SM could be a 
specific ligand restricted to the ancient metazoan Lipocalins, including ApoD and its 
insect related Lipocalins (NLaz and Laz). Retinol binding to α1-mg was used as a 
positive control (Fig. S3C). With these findings, the question of whether ApoD-
cholesterol relationships found in vivo [18, 51] are indirectly mediated by ApoD control 
of SM content of membranes or lipoprotein particles is also open for further research. 
 
Membrane phospholipids have been also suggested as ApoD ligands, though 
previous studies failed to show binding to phosphocholine [34]. We tested the binding 
of ApoD, NLaz and Laz to phosphoethanolamine, with PA as substituent in position 1 
and LA in position 2 (PLPE). Neither ApoD nor its insect homologues (NLaz and Laz) 
showed positive binding (Fig. S4D-F). Thus, with the available data, we can discard 
phospholipids as probable ligands for the ApoD Lipocalin group. An interesting 
antecedent is found in the Lipocalin literature: ApoM is only able to bind phospholipids 
with high affinity when they have been previously oxidized [56]. This property is still 
open for ApoD and other Lipocalins and might be related to the protective functions of 
many family members. 
 
2.1.3. Binding to steroid hormones. 
 
ApoD was characterized as a progesterone-binding protein from the cystic fluid of 
women with breast gross cystic disease [31]. This was confirmed by co-crystallizing 
ApoD and progesterone [36], and many groups have studied the role of ApoD in breast 
cancer [reviewed by 57]. Steroid hormone regulatory elements have been identified in 
the ApoD promoter, also suggesting such a link [58]. However, we show here that 
ApoD does not bind 17β-estradiol  (Fig. 3A), the other main steroid hormone involved 
in reproduction, as previously reported [32]. 
The steroid hormone 20-Hydroxyecdysone (20-E) plays crucial roles in larval 
molting and metamorphosis [reviewed by 59]. No binding was detected for NLaz with 
20-E in the micromolar range of concentrations (Fig. 3B), as we reported for 
bacterially-expressed recombinant Laz [40]. 
 
Therefore, ApoD, NLaz and Laz show a varied specificity for steroids. ApoD binds 
progesterone with high affinity, but it does not bind cholesterol, ergosterol or 17β-
estradiol. A possible explanation could be the presence of a hydroxyl substituent in 
position 3 of the cholesterol, ergosterol and 17β-estradiol molecules, which is replaced 
with a carboxyl group in progesterone. On the other hand, NLaz and Laz bind ergosterol 
but not 20-HE, which has two hydroxyl groups in positions 2 and 3. Binding of NLaz to 
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both ergosterol and cholesterol implies intermediate structural and surface properties in 
the NLaz Lipocalin calyx. 
 
2.1.4. Fatty acids and related lipids. 
 
Fatty acids have been frequently identified as Lipocalin ligands [reviewed by 48]. 
Both ApoD and Laz bind AA (20:4) [34, 35, 40], which is released from membrane 
phospholipids by phospholipase-A2, is a substrate for eicosanoids synthesis, and plays a 
critical role in inflammation and tissue homeostasis. Protection of AA oxidation by 
binding to ApoD, preventing its conversion to isoprostanes, has been suggested as a 
putative ApoD mechanism of action [51]. 
The relationship between ApoD and AA is also extended to neurological disorders. 
ApoD levels are increased in certain brain areas of patients with Alzheimer’s disease 
[14], Parkinson’s disease [15] or schizophrenia [16]. A common characteristic in these 
three pathologies is a reduction in the levels of AA in the brain [60-62]. Increased 
ApoD levels could be interpreted as an attempt to correct for low AA levels, to maintain 
the fluidity properties of plasma membranes and the function of AA signaling pathways. 
As ApoD-AA binding has already been well established, we tested if NLaz can 
bind other fatty acids such as arachidic acid (ArA) or PA, which are abundant in 
Drosophila sphingolipids and glycerophospholipids respectively [52]. Figure 4B-C 
shows a positive binding with ArA and PA. The estimated KD were 4.5 µM and 4.7 µM 
for NLaz-ArA and NLaz-PA respectively. 
NLaz-PA binding and the previously known Laz-PA binding [40], led us to test 
whether PA binding was also conserved in ApoD. Figure 4A shows the titration of PA 
with ApoD, resulting in a calculated KD of 3.3 µM. These results contrast with a 
previous report where ApoD does not measurably bind to PA [34]. Technical 
differences might underlay these results. While we used 295 nm, which selectively 
excites tryptophan residues, Morais-Cabral et al. [34] used 280 nm, that also excites 
tyrosine residues. Energy transfer from tyrosine to tryptophan is common and might 
complicate the interpretation of results. 
 
2.1.5. Endocannabinoids and ApoD. 
 
Endogenous cannabinoids, or endocannabinoids (EC), are lipid modulators of 
synaptic activity and are involved in memory, anxiety, movement and pain. 
Predominant ECs include anandamide (AEA) and 2-arachidonoylglycerol (2-AG). AEA 
and 2-AG are both synthesized from membrane AA glycerophospholipid precursors 
[reviewed by 63]. 
How ECs are released from cells and how they reach their targets is a major issue in 
the field. Recent studies have identified intracellular AEA transport proteins, but the 
question is still open on whether extracellular EC-transporter proteins exist [see 64 for a 
review]. It has been suggested that Lipocalins, due to their lipid binding pocket, could 
be responsible for EC mobilization inside the brain [65]. Three Lipocalins are normally 
expressed in the human brain: L-PGDS, RBP and ApoD. RBP and PGDS ligands are 
well known and their functions have been established. ApoD appears therefore as a 
likely candidate for EC binding. NLaz is also a brain Lipocalin, but the classical 
cannabinoid receptors are absent in the Drosophila brain [66]. 
These results, along with ApoD binding to the EC precursor AA [34, 35], point to 
this Lipocalin as an endocannabinoid carrier. We tested whether ApoD binds to 2-AG 
or AEA, and found measurable binding with AEA (KD 1.6 µM) (Fig. 4D, E). This is the 
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first experimental evidence showing an interaction between ApoD and the 
endocannabinoid system. This selective binding profile of ApoD is particularly 
noteworthy, and future in vivo experiments with ApoD-KO and ApoD-overexpressor 
mice might confirm a physiological role for ApoD in the endocannabinoid system. 
 
2.1.6. NLaz binding to Drosophila pheromones. 
 
Pheromones are bioactive lipids involved in the regulation of courtship behavior 
and mating. NLaz null mutant (NLaz-KO) flies exhibit a dramatically low courtship 
index compared to their isogenic controls [23, 27]. As a first step to understand the 
mechanistic origin of this phenotype, we tested whether NLaz is able to bind 
Drosophila pheromones. 
11-cis-vaccenyl acetate (cVA) is the most studied Drosophila pheromone, and acts 
selectively through the Or67b odorant receptor in both sexes [67]. LUSH is the 
extracellular carrier for cVA and undergoes a conformational change that triggers cVA 
release and binding to the Or67b receptor [68]. We tested NLaz as an alternative 
pheromone-binding protein for cVA, but did not detect significant binding (Fig. 3E).  
Other Drosophila cuticular sex pheromones are unsaturated long-chain 
hydrocarbons synthesized from fatty acid precursors. PA, a ligand of NLaz, is also the 
substrate of Desat1, a PA desaturase that triggers an enzymatic pheromone synthesis 
pathway [69]. 
Drosophila hydrocarbon pheromones are dimorphic: monoene hydrocarbons are 
predominant in males, and dienes in females [70]. We tested whether NLaz is able to 
bind two of the major Drosophila pheromones: the 7-tricosene (7-T, 23:1) and 7,11-
heptacosadiene (7,11-HD, 27:2). Figure 3C shows positive binding of NLaz to monoene 
7-T, whereas no binding was detected with the diene 7,11-HD (Fig. 3D). The estimated 
KD of 7-T binding to NLaz is 4.5 µM. 7-T increases Drosophila female sexual 
receptivity, making flies to mate faster and more often with males that have higher 
levels of 7-T, while low levels of 7-T reduces courtship success [71]. We propose that 
NLaz could be acting as a pheromone carrier protein for 7-T, in a way similar to the 
LUSH-cVA pair [68].  
 
2.2. ApoD-RA interaction is required for neuronal differentiation in culture. 
 
Finally, we assayed whether any of the binding properties of the ApoD-related 
Lipocalins have direct in vivo consequences. For that purpose, we chose a neuronal cell 
model (SH-SY5Y and M17 cell lines), and RA as a well-defined common ligand for 
these proteins. 
RA has a crucial role during brain development, being required to induce early 
progenitors to adopt a neural fate. During embryogenesis there is a requirement for a 
precise timing of exposure to RA and a coordinated pattern of expression of retinoic 
acid receptors (RARs) [see 43 for a general review].  
SH-SY5Y is a human neuroblastoma cell line that has been established as a model 
of neuronal differentiation [72, 73]. Under RA treatment SH-SY5Y cells develop long 
processes, and cells with processes longer than 50 µm have been considered as 
morphologically differentiated [72]. The presence of at least 1% serum [74] or 
exogenous albumin is required to obtain differentiation of SH-SY5Y cells by RA [75]. 
On the contrary, SH-SY5Y cells quickly enter the apoptosis pathway under serum 
deprivation [76]. 
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ApoD plays an active role during nervous system development, where it is mainly 
expressed by glial cells, but is also present in neurons during development [8-10] at 
times when neurite growth is taking place. ApoD has been previously related with cell 
differentiation. Lopez-Boado el al. [77] first described that human breast cancer T-47D 
cells differentiate under RA treatment. In these conditions T-47D cells accumulate lipid 
droplets and increase ApoD levels, both at mRNA and protein levels. This process is 
RARα-dependent [78]. Moreover, Kosacka et al. [30, 50] have shown that ApoD might 
act as a neurotrophic adipokine and exerts differentiating and synaptogenic effects in 
dorsal root ganglion neurons. On the other hand, when SH-SY5Y cells are transfected 
with p73, a transcription factor of the p53 family involved in neuronal differentiation, 
cells differentiate to mature neurons in an ApoD-dependent manner [79].  
Initially, we confirmed that SH-SY5Y extend neurites under standard 
differentiation conditions (Fig. 5B and 5C). When serum was removed from the 
medium, cell survival decreased dramatically and no differentiation was achieved even 
in the presence of RA, ApoD, NLaz or Laz (Fig. 5E-F and 6A-B). However, cells do 
differentiate and develop numerous long processes if we add ApoD preloaded with RA 
(Fig. 5G) in the absence of serum. These results show that ApoD is necessary and 
sufficient to allow for RA differentiating activity. 
To validate as general the effects of ApoD-RA on neuronal differentiation, we used 
another human neuroblastoma cell line, M17, and obtained identical results (Fig. S5 and 
S6B). 
Thus, ApoD loaded with RA produces neuronal differentiation and promotes 
neuritogenesis even under serum deprivation conditions. Since RA solubility in water is 
limited, we propose that ApoD could be acting as a carrier protein for RA. Astrocytes 
act as a source of ApoD [26] and also provide RA and contribute to RA homeostasis 
[80]. ApoD could therefore deliver, or make available, RA from astrocytes to neuronal 
precursors in vivo. 
Finally, we tested whether NLaz or Laz can also mediate the differentiation effect 
of RA on SH-SY5Y cells. RA-preloaded NLaz also induces neuronal differentiation, 
but in a less efficient way than ApoD-RA or serum-RA (Fig. 6C and E). However, the 
lengths of processes produced by NLaz-RA are similar to those under ApoD-RA or 
serum-RA treatment (Fig. S6A). On the other hand, SH-SY5Y cells treated with Laz-
RA do not show a different number of processes than control cells (Fig. 6D and E). 
 
In summary, SH-SY5Y cells treated with ApoD or NLaz, but not Laz, preloaded 
with RA are able to survive and differentiate in serum free medium, developing long 
processes. These results indicate that not every RA binding protein is able to trigger the 
differentiation program. Since NLaz-RA is not as successful as ApoD-RA in triggering 
SH-SY5Y differentiation, our results also suggests that a specific interaction, perhaps 
with an ApoD receptor, is further required to obtain the full effect. NLaz or Laz 
interaction with this putative receptor in mammalian cells might not be as favorable. 
In spite of the relevance of RA during early morphogenesis and nervous system 
development, and the fact that we find an ApoD-RA functional interaction, ApoD null 
mice do not have major developmental problems and reach adulthood with apparent 
normality [21]. They show, however, defects in locomotor and spatial memory tests [21 
and unpublished observations] revealing a certain extent of wiring defects. Since RA 
can in principle also bind to other Lipocalins present in the nervous system [e.g. 81, 82], 
functional redundancy might explain the ability of the ApoD-KO mice to complete their 
development without major alterations.  
 
11 
 
2.3. ApoD and its insect related Lipocalins: conservation and divergence of ligand 
binding properties.  
 
Many studies have shown that human ApoD, Drosophila NLaz and Schistocerca 
Laz share functional properties in the organism: regulation of lifespan, lipid and 
carbohydrate metabolism control and protection against oxidative stress or starvation 
[21, 22, 26, 27, 55]. This work extends the knowledge of ligand binding for ApoD and 
Laz, and presents an extensive ligand screening for NLaz. 
Our ligand-binding studies show that ApoD-NLaz-Laz similarities also extend to 
their biochemical and lipid binding properties. Homology modeling of the structures of 
Laz and NLaz (Fig. 7A) and a comparison of their sequences (Fig. 7C) show the 
presence of predicted ligand binding sites, broadly consistent with the conserved 
structures of Lipocalins and the ligand specificities reported here. Some of the ligands 
for which we have proven a positive interaction are shown at the same scale, either in 
full or as part of their molecular structure with a configuration most compatible with the 
ligand binding cavities (Fig. 7B).  
The modeled calyces of the insect Laz and NLaz are somewhat smaller in total 
volume and with moderately greater polar character than the ApoD calyx. As most 
Lipocalins, NLaz binds retinol and RA. Besides, fatty acids and SM are ligands 
common to ApoD and its insect related Lipocalins. Whether the SM polar head (shown 
in Fig. 7B) or its acyl groups are the main interacting moieties in this ligand remains to 
be resolved. We can predict that these common ligands can be related with in vivo 
common functions of ApoD, NLaz and Laz. In addition, a set of species-specific ligands 
are first described here. AEA binding to ApoD and 7-T to NLaz might represent new 
functions acquired by these Lipocalins during their divergent evolution. 
ApoD, NLaz and Laz can be considered as moonlighting proteins, and that 
pleiotropy is reflected on the high number of putative hydrophobic ligands. Their 
ligands belong to different groups of lipids, exhibiting different shapes and biochemical 
properties. In spite of this high variability and apparently promiscuous binding, ApoD, 
NLaz and Laz show a quite exquisite selectivity between very similar lipidic species. 
For example, ApoD binds the endocannabinoid AEA, but not 2-AG, and NLaz binds the 
pheromone 7-T but not 7,11-HD. 
Taken together, our ligand screening and the neuronal cell based assay should help 
us understand how ApoD, NLaz and Laz perform their known biological functions, and 
how much of each function can be dependent on the particular lipidic ligand involved. 
Furthermore, the discovery of new putative ligands for these Lipocalins opens the door 
to explore new functions of ApoD and Lazarillo in vivo. 
 
3. Materials and Methods 
 
3.1. Cell cultures. 
Drosophila S2 cells were cultured as previously described [27]. Human 
neuroblastoma cell lines SH-SY5Y and M17 were grown at 37ºC in a saturated 
humidity atmosphere containing 5% CO2 in DMEM (Dulbecco’s Modified Eagle’s 
Medium, Lonza Iberica, Barcelona, Spain) supplemented with glucose (4.5 g/l), heat-
inactivated 10% FBS (fetal bovine serum, Lonza Iberica), 1% L-Glutamine, antibiotics 
(penicillin, 10 U/μl; streptomycin, 10 μg/μl; amphotericin B, 25 μg/ml; Lonza Iberica), 
and 1% non-essential amino acids (NEAA, Lonza Iberica). The culture medium was 
replaced twice a week, and cells were subcultured at 90% confluence. 
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3.2. Cloning and protein purification of NLaz, Laz and ApoD. 
The NLaz full-length cDNA, translating into residues 1-224 (CG33126, Uniprot 
reference Q9NAZ4, FlyBase entry FBgn0053126), and a fragment of Lazarillo cDNA 
encoding a 192 residue fragment missing the GPI signal peptide (Uniprot reference 
P49291), were subcloned into the pRmHa3 vector using EcoRI and NotI sites. This 
system expresses the cloned sequences under the control of an inducible Drosophila 
metallothionein promoter and incorporates a C-terminal poly-histidine sequence 
allowing for protein purification from conditioned medium. 
NLaz-pRmHa3 or Lazarillo-pRmHa3 plasmids were co-transfected with a pCoBlast 
selection vector (conferring blasticidin resistance) into Drosophila S2 cells. Protein 
expression induction and purification were performed as previously described [27], 
adding two rounds of size exclusion chromatography purification after the initial metal 
affinity chromatography (Fig. S1B-D). 
Bacterial recombinant Laz was purified from the periplasmic space of E. coli as 
previously described [40]. Human ApoD  (hApoD) was purified from breast cystic fluid 
(Fig. S1A and S1D) by ion-exchange chromatography (UNO-Q, BioRad, Hercules, CA, 
USA) in 25 mM Tris pH 8.0 followed by size exclusion chromatography (P60, BioRad) 
in 50 mM Tris pH 8.0, 75 mM NaCl. Protein purity was determined by SDS-PAGE and 
integrated optical density of the protein bands stained with Coomassie was measured, 
resulting in 91% purity for ApoD and >98% purity for NLaz and Laz (Fig. S1). 
 
3.3. Ligand binding assays by tryptophan fluorescence titration. 
Fluorescence measurements were conducted with a Shimadzu RF-5301PC 
spectrofluorometer in a quartz cuvette (Hellma, Müllheim, Germany, 105.251-QS, 3 
mm-path length). Temperature was held at 22 ± 0.1ºC. The excitation wavelength was 
295 nm (selective for tryptophan residues). Emission was recorded from 327 to 400 nm 
with slit width set at 5 nm. The peak observed at 340 nm was measured and used to 
calculate the apparent equilibrium dissociation constant (KD). Data analysis was 
performed with the RFPC software package (Shimadzu, Kyoto, Japan). NLaz and the 
control protein α1-microglobulin were diluted to a concentration of 1 μM in 10 mM 
phosphate buffer, 150 mM NaCl, 1 mM EDTA at pH 7.0. Laz and hApoD were diluted 
to a concentration of 0.5 μM in the same buffer, so that the starting intrinsic 
fluorescence of all proteins lies within the same dynamic range of measurement. The 
ligands tested were: retinoic acid, retinol, non-esterified cholesterol, ergosterol, β-
estradiol, palmitic acid (Sigma St. Louis, MO, USA ); palmitoyl-sphingomyelin, 
arachidic acid, 7(z)-tricosene, 7(z),11(z)-heptacosadiene, 11-cis-vaccenyl acetate, 
palmitoyl-linoleyl-phosphoethanolamine, 2-arachidonylglycerol, anandamide (Cayman, 
Tallinn, Estonia); and 20-hydroxyecdysone (Santa Cruz Biotechnology, Dallas, TX, 
USA). All ligands were dissolved in N,N-dimethylformamide (DMF; Sigma) to make 
concentrated stock solutions within their solubility range. A four step titration was 
performed, adding each time 1 µl aliquots of the ligand to a 100 µl volume of protein 
solution. The mixtures were equilibrated for 3 min in the dark before the fluorescence 
was recorded. 
The fluorescence spectrum in the presence of a ligand was subtracted from a DMF 
baseline obtained by titration of the protein with the same amounts of carrier without 
ligand. The corrected fluorescence at 340 nm versus ligand concentration was fitted as 
previously described [37, 40]. KD was calculated under the assumption of a single 
binding site, consistent with known Lipocalin structural properties, regardless of 
whether ligand binding enhances or quenches tryptophan fluorescence. A tryptophan 
residue conserved along the entire Lipocalin family is located at the binding pocket 
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surface, and is predicted to be the residue responsible for most of the intrinsic 
fluorescence changes observed. The specificity of protein fluorescence variation was 
tested by performing the assay with the protein denatured with 5 M guanidine 
hydrochloride in the same buffer for 21 h before measurement (Fig. S2). 
 
3.4. Neuronal cell line differentiation assay. 
SH-SY5Y or M17 cells were seeded at 20,000/cm2 in 24 well plates (Nunc) with 
standard medium. After 12 h, the medium was replaced. New medium was added with 
or without serum or additives (protein, ligand or equimolar amounts of both protein and 
ligand). Retinoic acid and retinol stock solutions were prepared in ethanol and diluted in 
medium to a final concentration of 1 or 10 μM. The carrier concentration was kept at 
0.1 % (v/v). The concentrations of hApoD, NLaz and Lazarillo were measured by 
MicroBCA-assay (Pierce, Rockford, IL, USA) and the proteins were diluted in sterile 
PBS to prepare the working protein stocks. Equimolar protein-ligand mixtures were 
incubated in the dark at room temperature for five minutes to allow for complexation 
before addition to cells. SH-SY5Y cultures were analyzed after 4-6 days of growth in 
the presence of additives, and M17 cultures were analyzed after 3-4 days of growth. 
Photomicrographs were analyzed with NISelements software (Nikon) with 
morphological differentiation determined by the number of neurites (processes longer 
than 50 μm) present per field [72]. 
 
3.5. Statistical analysis. 
Statistical analyses were performed with Sigma Plot software (v 11.0). Kruskal-
Wallis one-way ANOVA on Ranks followed by Dunn’s multiple comparison post-hoc 
tests were used in the analysis of neurite promoting activity of Lipocalins. A p-value < 
0.05, marked with an asterisk, was used as a threshold for significant changes. Two 
asterisks were used for p <0.001. 
 
 
4. Acknowledgments 
 
We thank Dr. Bo Åkerström who kindly donated the α-1-microglobulin protein purified 
from a bacterial expression system. We thank Dr. Sonia Gallego for SH-SY5Y cells, 
and Dr. R. Bajo-Grañeras and Dr. Angel Cedazo for M17 cell lines donation. E. Martin-
Tejedor provided technical assistance throughout the project. 
 
Grant support. This work was supported by grants to M.D.G. and D.S. (Junta de 
Castilla y León (JCyL) grant VA180A11-2, and Ministerio de Ciencia e Innovación 
(MICINN) grants BFU2008-01170 and BFU2011-23978). M.R. was supported by a 
JCyL fellowship to young researchers (call#EDU/1708/2008). 
 
 
5. References 
 
1. Newcomer ME & Ong DE (2006) Retinol Binding Protein and Its Interaction 
with Transthyretin. In Lipocalins (Åkerström B, Borregaard N, Flower DR & Salier JP, 
ed^eds). Landes Bioscience, Georgetown, Texas. 
14 
 
2. Sevvana M, Ahnstrom J, Egerer-Sieber C, Lange HA, Dahlback B & Muller YA 
(2009) Serendipitous fatty acid binding reveals the structural determinants for ligand 
recognition in apolipoprotein M. J Mol Biol 393, 920-936. 
3. Urade Y, Eguchi N & Osamu Hayaishi O (2006) Lipocalin-Type Prostaglandin 
D Synthase as an Enzymic Lipocali. In Lipocalins (Åkerström B, Borregaard N, Flower 
DR & Salier JP, ed^eds). Landes Bioscience, Georgetown, Texas. 
4. Flower DR, North AC & Sansom CE (2000) The lipocalin protein family: 
structural and sequence overview. Biochim Biophys Acta 1482, 9-24. 
5. Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L & Milne R 
(2000) Apolipoprotein D. Biochim Biophys Acta 1482, 185-198. 
6. McConathy WJ & Alaupovic P (1976) Studies on the isolation and partial 
characterization of apolipoprotein D and lipoprotein D of human plasma. Biochemistry 
15, 515-520. 
7. Goessling W & Zucker SD (2000) Role of apolipoprotein D in the transport of 
bilirubin in plasma. Am J Physiol Gastrointest Liver Physiol 279, G356-365. 
8. Ong WY, Lau CP, Leong SK, Kumar U, Suresh S & Patel SC (1999) 
Apolipoprotein D gene expression in the rat brain and light and electron microscopic 
immunocytochemistry of apolipoprotein D expression in the cerebellum of neonatal, 
immature and adult rats. Neuroscience 90, 913-922. 
9. Sanchez D, Ganfornina MD & Martinez S (2002) Expression pattern of the 
lipocalin apolipoprotein D during mouse embryogenesis. Mech Dev 110, 225-229. 
10. Ganfornina MD, Sanchez D, Pagano A, Tonachini L, Descalzi-Cancedda F & 
Martinez S (2005) Molecular characterization and developmental expression pattern of 
the chicken apolipoprotein D gene: implications for the evolution of vertebrate 
lipocalins. Dev Dyn 232, 191-199. 
11. Kim WS, Wong J, Weickert CS, Webster MJ, Bahn S & Garner B (2009) 
Apolipoprotein-D expression is increased during development and maturation of the 
human prefrontal cortex. J Neurochem 109, 1053-1066. 
12. Loerch PM, Lu T, Dakin KA, Vann JM, Isaacs A, Geula C, Wang J, Pan Y, 
Gabuzda DH, Li C, Prolla TA & Yankner BA (2008) Evolution of the aging brain 
transcriptome and synaptic regulation. PLoS One 3, e3329. 
13. de Magalhaes JP, Curado J & Church GM (2009) Meta-analysis of age-related 
gene expression profiles identifies common signatures of aging. Bioinformatics 25, 875-
881. 
14. Terrisse L, Poirier J, Bertrand P, Merched A, Visvikis S, Siest G, Milne R & 
Rassart E (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and 
hippocampus of Alzheimer's patients. J Neurochem 71, 1643-1650. 
15 
 
15. Ordonez C, Navarro A, Perez C, Astudillo A, Martinez E & Tolivia J (2006) 
Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol 
Histopathol 21, 361-366. 
16. Thomas EA, Dean B, Pavey G & Sutcliffe JG (2001) Increased CNS levels of 
apolipoprotein D in schizophrenic and bipolar subjects: implications for the 
pathophysiology of psychiatric disorders. Proc Natl Acad Sci U S A 98, 4066-4071. 
17. Kroksveen AC, Aasebo E, Vethe H, Van Pesch V, Franciotta D, Teunissen CE, 
Ulvik RJ, Vedeler C, Myhr KM, Barsnes H & Berven FS (2012) Discovery and initial 
verification of differentially abundant proteins between multiple sclerosis patients and 
controls using iTRAQ and SID-SRM. J Proteomics. 
18. Suresh S, Yan Z, Patel RC, Patel YC & Patel SC (1998) Cellular cholesterol 
storage in the Niemann-Pick disease type C mouse is associated with increased 
expression and defective processing of apolipoprotein D. J Neurochem 70, 242-251. 
19. Ganfornina MD, Gutierrez G, Bastiani M & Sanchez D (2000) A phylogenetic 
analysis of the lipocalin protein family. Mol Biol Evol 17, 114-126. 
20. Sanchez D, Ganfornina MD, Gutierrez G & Marin A (2003) Exon-intron 
structure and evolution of the Lipocalin gene family. Mol Biol Evol 20, 775-783. 
21. Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn 
M, González C, Bastiani MJ, Rassart E & Sanchez D (2008) Apolipoprotein D is 
involved in the mechanisms regulating protection from oxidative stress. Aging Cell 7, 
506-515. 
22. Hull-Thompson J, Muffat J, Sanchez D, Walker DW, Benzer S, Ganfornina MD 
& Jasper H (2009) Control of metabolic homeostasis by stress signaling is mediated by 
the lipocalin NLaz. PLoS Genet 5, e1000460. 
23. Ruiz M, Sanchez D, Canal I, Acebes A & Ganfornina MD (2011) Sex-dependent 
modulation of longevity by two Drosophila homologues of human Apolipoprotein D, 
GLaz and NLaz. Exp Gerontol 46, 579-589. 
24. Do Carmo S, Fournier D, Mounier C & Rassart E (2009) Human apolipoprotein 
D overexpression in transgenic mice induces insulin resistance and alters lipid 
metabolism. Am J Physiol Endocrinol Metab 296, E802-811. 
25. Jimenez-Palomares M, Cozar-Castellano I, Ganfornina MD, Sanchez D & 
Perdomo G (2011) Genetic deficiency of apolipoprotein D in the mouse is associated 
with nonfasting hypertriglyceridemia and hyperinsulinemia. Metabolism 60, 1767-1774. 
26. Bajo-Graneras R, Ganfornina MD, Martin-Tejedor E & Sanchez D (2011) 
Apolipoprotein D mediates autocrine protection of astrocytes and controls their 
reactivity level, contributing to the functional maintenance of paraquat-challenged 
dopaminergic systems. Glia 59, 1551-1566. 
27. Ruiz M, Wicker-Thomas C, Sanchez D & Ganfornina MD (2012) Grasshopper 
Lazarillo, a GPI-anchored Lipocalin, increases Drosophila longevity and stress 
16 
 
resistance, and functionally replaces its secreted homolog NLaz. Insect Biochem Mol 
Biol 42, 776-789. 
28. Zhang Y, Cong Y, Wang S & Zhang S (2011) Antioxidant activities of 
recombinant amphioxus (Branchiostoma belcheri) apolipoprotein D. Mol Biol Rep 38, 
1847-1851. 
29. Bhatia S, Knoch B, Wong J, Kim WS, Else PL, Oakley AJ & Garner B (2012) 
Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives 
by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease. 
Biochem J 442, 713-721. 
30. Kosacka J, Schroder T, Bechmann I, Kloting N, Nowicki M, Mittag A, Gericke 
M, Spanel-Borowski K & Bluher M (2011) PACAP up-regulates the expression of 
apolipoprotein D in 3T3-L1 adipocytes. DRG/3T3-L1 co-cultures study. Neurosci Res 
69, 8-16. 
31. Pearlman WH, Gueriguian JL & Sawyer ME (1973) A specific progesterone-
binding component of human breast cyst fluid. J Biol Chem 248, 5736-5741. 
32. Lea OA (1988) Binding properties of progesterone-binding Cyst protein, PBCP. 
Steroids 52, 337-338. 
33. Dilley WG, Haagensen DE, Cox CE & Wells SA, Jr. (1990) Immunologic and 
steroid binding properties of the GCDFP-24 protein isolated from human breast gross 
cystic disease fluid. Breast Cancer Res Treat 16, 253-260. 
34. Morais Cabral JH, Atkins GL, Sanchez LM, Lopez-Boado YS, Lopez-Otin C & 
Sawyer L (1995) Arachidonic acid binds to apolipoprotein D: implications for the 
protein's function. FEBS Lett 366, 53-56. 
35. Vogt M & Skerra A (2001) Bacterially produced apolipoprotein D binds 
progesterone and arachidonic acid, but not bilirubin or E-3M2H. J Mol Recognit 14, 79-
86. 
36. Eichinger A, Nasreen A, Kim HJ & Skerra A (2007) Structural insight into the 
dual ligand specificity and mode of high density lipoprotein association of 
apolipoprotein D. J Biol Chem 282, 31068-31075. 
37. Breustedt DA, Schonfeld DL & Skerra A (2006) Comparative ligand-binding 
analysis of ten human lipocalins. Biochim Biophys Acta 1764, 161-173. 
38. Zeng C, Spielman AI, Vowels BR, Leyden JJ, Biemann K & Preti G (1996) A 
human axillary odorant is carried by apolipoprotein D. Proc Natl Acad Sci U S A 93, 
6626-6630. 
39. Patel RC, Lange D, McConathy WJ, Patel YC & Patel SC (1997) Probing the 
structure of the ligand binding cavity of lipocalins by fluorescence spectroscopy. 
Protein Eng 10, 621-625. 
17 
 
40. Sanchez D, Ortega-Cubero S, Åkerström B, Herrera M, Bastiani MJ & 
Ganfornina MD (2008) Molecular interactions of the neuronal GPI-anchored lipocalin 
Lazarillo. Journal of Molecular Recognition 21, 313-323. 
41. Goodman DS (1980) Plasma retinol-binding protein. Ann N Y Acad Sci 348, 
378-390. 
42. Biesalski HK, Frank J, Beck SC, Heinrich F, Illek B, Reifen R, Gollnick H, 
Seeliger MW, Wissinger B & Zrenner E (1999) Biochemical but not clinical vitamin A 
deficiency results from mutations in the gene for retinol binding protein. Am J Clin Nutr 
69, 931-936. 
43. Rhinn M & Dolle P (2012) Retinoic acid signalling during development. 
Development 139, 843-858. 
44. Nowickyj SM, Chithalen JV, Cameron D, Tyshenko MG, Petkovich M, Wyatt 
GR, Jones G & Walker VK (2008) Locust retinoid X receptors: 9-Cis-retinoic acid in 
embryos from a primitive insect. Proc Natl Acad Sci U S A 105, 9540-9545. 
45. Sanchez D, Ganfornina MD & Bastiani MJ (2000) Lazarillo, a neuronal 
lipocalin in grasshoppers with a role in axon guidance. Biochim Biophys Acta 1482, 
102-109. 
46. McConathy WJ & Alaupovic P (1973) Isolation and partial characterization of 
apolipoprotein D: a new protein moiety of the human plasma lipoprotein system. FEBS 
Lett 37, 178-182. 
47. Blanco-Vaca F, Via DP, Yang CY, Massey JB & Pownall HJ (1992) 
Characterization of disulfide-linked heterodimers containing apolipoprotein D in human 
plasma lipoproteins. J Lipid Res 33, 1785-1796. 
48. Akerström B, Borregaard N, Flover D & Salier J (2006) Lipocalins, 
Georgetown, Texas. 
49. Perdomo G, Kim DH, Zhang T, Qu S, Thomas EA, Toledo FG, Slusher S, Fan 
Y, Kelley DE & Dong HH (2010) A role of apolipoprotein D in triglyceride 
metabolism. J Lipid Res 51, 1298-1311. 
50. Kosacka J, Gericke M, Nowicki M, Kacza J, Borlak J & Spanel-Borowski K 
(2009) Apolipoproteins D and E3 exert neurotrophic and synaptogenic effects in dorsal 
root ganglion cell cultures. Neuroscience 162, 282-291. 
51. He X, Jittiwat J, Kim JH, Jenner AM, Farooqui AA, Patel SC & Ong WY (2009) 
Apolipoprotein D modulates F2-isoprostane and 7-ketocholesterol formation and has a 
neuroprotective effect on organotypic hippocampal cultures after kainate-induced 
excitotoxic injury. Neurosci Lett 455, 183-186. 
52. Rietveld A, Neutz S, Simons K & Eaton S (1999) Association of sterol- and 
glycosylphosphatidylinositol-linked proteins with Drosophila raft lipid microdomains. J 
Biol Chem 274, 12049-12054. 
18 
 
53. Vance DE & Vance JE (2008) Biochemistry of Lipids, Lipoproteins and 
Membranes, 5th edn. Elsevier. 
54. Nagao K, Takahashi K, Hanada K, Kioka N, Matsuo M & Ueda K (2007) 
Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-
deficient Chinese hamster ovary cells. J Biol Chem 282, 14868-14874. 
55. Ganfornina MD, Do Carmo S, Martínez E, Tolivia J, Navarro A, Rassart E & 
Sanchez D (2010) ApoD, a glia-derived apolipoprotein, is required for peripheral nerve 
functional integrity and a timely response to injury. Glia 58, 1320-1334. 
56. Elsoe S, Ahnstrom J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke 
JW, Binder CJ, Bjorkbacka H, Dahlback B & Nielsen LB (2012) Apolipoprotein M 
binds oxidized phospholipids and increases the antioxidant effect of HDL. 
Atherosclerosis 221, 91-97. 
57. Soiland H, Soreide K, Janssen EA, Korner H, Baak JP & Soreide JA (2007) 
Emerging concepts of apolipoprotein D with possible implications for breast cancer. 
Cell Oncol 29, 195-209. 
58. Lambert J, Provost PR, Marcel YL & Rassart E (1993) Structure of the human 
apolipoprotein D gene promoter region. Biochim Biophys Acta 1172, 190-192. 
59. Truman JW (2005) Hormonal control of insect ecdysis: endocrine cascades for 
coordinating behavior with physiology. Vitam Horm 73, 1-30. 
60. Fraser T, Tayler H & Love S (2010) Fatty acid composition of frontal, temporal 
and parietal neocortex in the normal human brain and in Alzheimer's disease. 
Neurochem Res 35, 503-513. 
61. Fabelo N, Martin V, Santpere G, Marin R, Torrent L, Ferrer I & Diaz M (2011) 
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's 
disease and incidental Parkinson's disease. Mol Med 17, 1107-1118. 
62. Yao JK, Leonard S & Reddy RD (2000) Membrane phospholipid abnormalities 
in postmortem brains from schizophrenic patients. Schizophr Res 42, 7-17. 
63. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M & Watanabe M 
(2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89, 
309-380. 
64. Fowler CJ (2012) Anandamide uptake explained? Trends Pharmacol Sci 33, 
181-185. 
65. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev 
Neurosci 4, 873-884. 
66. McPartland J, Di Marzo V, De Petrocellis L, Mercer A & Glass M (2001) 
Cannabinoid receptors are absent in insects. J Comp Neurol 436, 423-429. 
67. Kurtovic A, Widmer A & Dickson BJ (2007) A single class of olfactory neurons 
mediates behavioural responses to a Drosophila sex pheromone. Nature 446, 542-546. 
19 
 
68. Laughlin JD, Ha TS, Jones DN & Smith DP (2008) Activation of pheromone-
sensitive neurons is mediated by conformational activation of pheromone-binding 
protein. Cell 133, 1255-1265. 
69. Labeur C, Dallerac R & Wicker-Thomas C (2002) Involvement of desat1 gene 
in the control of Drosophila melanogaster pheromone biosynthesis. Genetica 114, 269-
274. 
70. Ferveur JF (2005) Cuticular hydrocarbons: their evolution and roles in 
Drosophila pheromonal communication. Behav Genet 35, 279-295. 
71. Grillet M, Dartevelle L & Ferveur JF (2006) A Drosophila male pheromone 
affects female sexual receptivity. Proc Biol Sci 273, 315-323. 
72. Pahlman S, Ruusala AI, Abrahamsson L, Mattsson ME & Esscher T (1984) 
Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a 
comparison with phorbolester-induced differentiation. Cell Differ 14, 135-144. 
73. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C & 
Comella JX (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-
derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-
dependent, human neuron-like cells. J Neurochem 75, 991-1003. 
74. Lopes FM, Schroder R, da Frota ML, Jr., Zanotto-Filho A, Muller CB, Pires AS, 
Meurer RT, Colpo GD, Gelain DP, Kapczinski F, Moreira JC, Fernandes Mda C & 
Klamt F (2010) Comparison between proliferative and neuron-like SH-SY5Y cells as an 
in vitro model for Parkinson disease studies. Brain Res 1337, 85-94. 
75. Nordin-Andersson M, Walum E, Kjellstrand P & Forsby A (2003) Acrylamide-
induced effects on general and neurospecific cellular functions during exposure and 
recovery. Cell Biol Toxicol 19, 43-51. 
76. Andoh T, Chock PB & Chiueh CC (2002) The roles of thioredoxin in protection 
against oxidative stress-induced apoptosis in SH-SY5Y cells. J Biol Chem 277, 9655-
9660. 
77. Lopez-Boado YS, Tolivia J & Lopez-Otin C (1994) Apolipoprotein D gene 
induction by retinoic acid is concomitant with growth arrest and cell differentiation in 
human breast cancer cells. J Biol Chem 269, 26871-26878. 
78. Lopez-Boado YS, Klaus M, Dawson MI & Lopez-Otin C (1996) Retinoic acid-
induced expression of apolipoprotein D and concomitant growth arrest in human breast 
cancer cells are mediated through a retinoic acid receptor RARalpha-dependent 
signaling pathway. J Biol Chem 271, 32105-32111. 
79. Sasaki Y, Negishi H, Koyama R, Anbo N, Ohori K, Idogawa M, Mita H, Toyota 
M, Imai K, Shinomura Y & Tokino T (2009) p53 family members regulate the 
expression of the apolipoprotein D gene. J Biol Chem 284, 872-883. 
80. Shearer KD, Fragoso YD, Clagett-Dame M & McCaffery PJ (2012) Astrocytes 
as a regulated source of retinoic acid for the brain. Glia 60, 1964-1976. 
20 
 
81. Nagata A, Suzuki Y, Igarashi M, Eguchi N, Toh H, Urade Y & Hayaishi O 
(1991) Human brain prostaglandin D synthase has been evolutionarily differentiated 
from lipophilic-ligand carrier proteins. Proc Natl Acad Sci U S A 88, 4020-4024. 
82. Zhang PX, Zhang FR, Xie JJ, Tao LH, Lu Z, Xu XE, Shen J, Xu LY & Li EM 
(2012) Expression of NGAL and NGALR in human embryonic, fetal and normal adult 
tissues. Mol Med Rep 6, 716-722. 
83. Holden HM, Rypniewski WR, Law JH & Rayment I (1987) The molecular 
structure of insecticyanin from the tobacco hornworm Manduca sexta L. at 2.6 A 
resolution. EMBO J 6, 1565-1570. 
 
  
  
21 
 
Figure Legends 
 
Fig. 1. 
Relative fluorescence intensity of hApoD and its insect homologues NLaz and Laz 
exposed to increasing concentrations of retinoic acid or retinol. hApoD and Laz protein 
concentration was 0.5 μM in 10 mM phosphate buffer, 150 mM NaCl, 1 mM EDTA at 
pH 7.0. NLaz concentration was 1 μM in the same buffer. (A) hApoD-RA; (B) NLaz-
RA; (C) Laz-RA; (D) hApoD-retinol; (E) NLaz-retinol; (F) Laz-retinol. Dots represent 
the mean of at least 5 independent titrations. 
 
Fig. 2. 
Intrinsic fluorescence changes of hApoD, NLaz and Laz upon incubation with different 
lipids present in biological membranes. (A) Stable fluorescence of hApoD upon 
exposure to increasing concentrations of cholesterol. (B) NLaz fluorescence 
enhancement by ergosterol. (C) Laz fluorescence enhancement by ergosterol. (D-F). 
Palmitoyl-sphingomyelin enhances the fluorescence of hApoD, NLaz and Laz. Dots 
represent the mean of at least 3 independent titrations. 
 
Fig. 3. 
Binding assays of hApoD and NLaz with hormones and pheromones. (A) β-estradiol 
does not alter the intrinsic fluorescence of hApoD. (B) NLaz does not bind 20-
hydroxyecdysone. (C) NLaz selectively binds the pheromone 7(z)-tricosene, whereas no 
interaction was detected for 7(z),11(z)-heptacosadiene (D), or 11-cis-vaccenyl acetate 
(E). Dots represent the mean of at least independent 3 titrations. 
 
Fig. 4. 
Interaction study of fatty acids and arachidonic acid-related molecules with hApoD 
and/or NLaz. (A, B) hApoD and NLaz bind palmitic acid. (C) NLaz is also able to bind 
arachidic acid. (D-E) Binding of ApoD to endocannabinoids. hApoD does not bind 2-
arachidonyl glycerol (D), but anandamide successfully interacts with hApoD enhancing 
its fluorescence (E). Dots represent the mean of at least independent 3 titrations. 
 
Fig. 5. 
Physiological role of RA and hApoD in neuronal differentiation. (A) SH-SY5Y cells 
growing in complete medium (10% FBS) with ethanol carrier. (B-C) Cells cultured in 
complete medium after 4-6 days of incubation with 10 μM RA (B) or 1 μM RA (C) in 
ethanol. (D) Cells cultured in serum-free medium plus carrier. (E-G) Serum-free 
medium was supplemented with 1 μM RA (E), 1 μM hApoD (F) or a mixture of 1 μM 
RA and 1 μM hApoD (G). Cell growth was monitored after 4-6 days in culture. (H) 
Quantification of the number of neurites observed per field. Bars represent the 
quantification of 8-18 fields per condition from 5-6 independent experiments. Kruskal-
Wallis one-way ANOVA on Ranks (p < 0.001) followed by Dunn’s multiple 
comparison post-hoc test. In SH-SY5Y cells hApoD is able to substitute for FBS to 
allow maturation and neurite growth. 
 
Fig. 6. 
Effects of long-term RA and/or NLaz-Laz treatments on SH-SY5Y cell differentiation. 
Cells grown in serum-free medium containing: (A) 1 μM NLaz, (B) 1 μM Laz, (C) 1 
μM RA plus 1 μM NLaz or (D) 1 μM RA plus 1 μM Laz. (E) Quantification of neurites 
observed per field normalized by the number of cells per field in each condition. Bars 
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represent the quantification of 8-16 photographs from 4-5 independent experiments. 
Kruskal-Wallis one-way ANOVA on Ranks (p<0.001) followed by Dunn’s multiple 
comparison post-hoc test. NLaz and RA are able to induce some degree of 
differentiation on SH.SY5Y cells, whereas Laz does not produce any effect. 
 
Fig. 7. 
Sequence and structure comparisons of ApoD with NLaz and Laz. (A) Cutaway views 
of the molecular surfaces of the crystal structure (PDB accession code 2HZQ, [36]) of 
ApoD and the homology models of Laz and NLaz are shown, colored by electrostatic 
potential, highlighting the calyces. Images were prepared with the PyMOL Molecular 
Graphics System, Version 1.3 (Schrödinger, LLC.). The progesterone ligand of ApoD is 
shown in a licorice stick representation, colored by atom type. Homology models were 
generated with SWISS-MODEL using the crystal structure of insecticyanin from the 
tobacco hornworm Manduca sexta (PDB accession code 1Z24, [83]) as a template. (B) 
Examples of ligands showing binding to at least one of the three Lipocalins are shown 
to scale. Either the complete molecule (RA, ergosterol) or parts of it (SM) are shown. 
(C) Sequence alignment showing ApoD-progesterone contact residues and 
corresponding amino acids in NLaz and Laz (highlighted in green). The conserved W 
(also an ApoD-progesterone interacting residue) is highlighted in orange. Structurally 
conserved regions (SCR) in the Lipocalin family are shown in brackets. β-strands are 
indicated by arrows and the α–helix by a cylinder. Asterisks mark the conserved 
cysteines, forming disulfide bonds. 
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Supplementary Figure Legends 
 
Fig. S1. 
Expression and purification of hApoD from human breast cystic fluid, and NLaz and 
Laz from S2 cells. Representative size-exclusion chromatography elution profile of 
hApoD (P60) (A), NLaz (analytical grade-200 column) (B), and Laz (analytical grade-
200 column) (C). (D) SDS-PAGE analysis of the purified Lipocalins. 
 
Fig. S2. 
Lack of retinoic acid binding to hApoD (A), NLaz (B) and Laz (C) under denaturing 
conditions. Binding assays were performed either in the standard buffer or after 21 h 
incubation with 5 M guanidine hydrochloride. Lipocalins-RA interaction depends on the 
protein tertiary structure. 
 
Fig. S3. 
Additional intrinsic fluorescence titration studies. Recombinant Laz purified from E. 
coli reproduces the binding pattern of Laz purified from S2 cells. (A) Laz binds retinoic 
acid and (B) palmitoyl-sphingomyelin. A different Lipocalin (α1-mg) also binds retinol 
(C), but does not bind palmitoyl-sphingomyelin (D). 
 
Fig. S4. 
Additional intrinsic fluorescence titration studies. (D) hApoD, (E) Nlaz and (F) Laz do 
not bind the phospholipid PLPE. 
 
Fig. S5. 
Confirmation of the physiological role of RA and hApoD in M17 cells, a different 
human neuronal cell line. Morphology changes of M17 cells growing in complete 
medium with (A) ethanol carrier, and after treatment with (B) 10 μM RA or (C) 1 μM 
RA in complete medium. (D) Cells in serum-free medium with ethanol carrier. (E-G) 
Cell differentiation after 4-6 days of treatment with (E) 1 μM RA, (F) 1 μM hApoD, or 
(G) 1 μM RA plus 1 μM hApoD. (H) Quantification of the number of neurite processes 
/field normalized by the number of cells/field in each condition. Bars represent the 
quantification of 10-25 fields per condition from 3 independent experiments. Kruskal-
Wallis one-way ANOVA on Ranks (p<0.001) followed by Dunn’s multiple comparison 
post-hoc test. In M17 cells, hApoD is also able to substitute for serum and to allow 
maturation and neurite growth. 
 
Fig. S6. 
Quantification of neurite length upon RA-induced differentiation of (A) SH-SY5Y or 
(B) M17 neuronal cell lines. No changes are observed in the length of neurites between 
treatments. Kruskal-Wallis one-way ANOVA on Ranks (p>0.05). 
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Fig.S1.
Expression and purification of hApoD from human breast cystic fluid, and of NLaz and 
Laz from S2 cells. Size-exclusion chromatography elution profile of hApoD (P60) (A), 
NLaz (analytical grade-200 column) (B), and Laz (analytical grade-200 column) (C). 
(D) SDS-PAGE analysis of the purified Lipocalins.
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Fig S2.
Additional intrinsic fluorescence quenching studies. Recombinant Laz purified from E.
coli reproduces the binding pattern of Laz purified from S2 cells. Laz binds retinoic acid
(A) and palmitoyl-sphingomyelin (B). A different Lipocalin (α1-mg) also binds retinol
(C), but does not bind palmitoyl-sphingomyelin (D).
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Lack of retinoic acid binding to hApoD 
(A), NLaz (B) and Laz (C) under 
denaturing conditions. Binding assay 
was performed either in the standard 
buffer or after 21 h incubation with 5 M 
guanidine hydrochloride. Lipocalins-RA 
interaction depends on the protein 
tertiary structure.
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Fig S4.
Additional intrinsic fluorescence quenching studies. hApoD cannot bind ergosterol (A). NLaz (B), but not Laz 
(C) binds cholesterol. Neither hApoD (D), NLaz (E), nor Laz (F) are able to bind the phospholipid PLPE.
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Fig S5.
Confirmation of the physiological role of RA and hApoD in M17 cells, a different human neuronal cell line. 
Morphology of M17 cells growing in complete medium with ethanol carrier (A), and after treatment with 
10 μM RA (B) or 1 μM RA (C) in complete medium. Cells in Serum-free medium with ethanol carrier (D); 
Cell differentiation after 4-6 days of treatmet with 1 μM RA (E), 1 μM hApoD (F), or 1 μM RA plus 1 mM 
hApoD (G). (H) Quantification of the number of neurite processes observed per field normalized by the 
number of cells per field in each condition. Bars represent the quantification of 10-25 fields per condition 
from 3 independent experiments. Kruskal-Wallis one-way ANOVA on Ranks (p<0.001) followed by 
Dunn’s multiple comparison post-hoc test. In M17 cells, hApoD is also able to substitute for serum and to 
allow maturation and neurite growth.
Page 2 of 2
Fig. S6
40
60
80
100
120
140
L
o
n
g
i
t
u
d
e
 
o
f
 
P
r
o
c
e
s
s
e
s
 
(
μ
m
)
p=0.259
50
100
150
200
250
300
L
o
n
g
i
t
u
d
e
 
o
f
 
P
r
o
c
e
s
s
e
s
 
(
μ
m
)
p=0.660
SH-SY5Y M17A B
10% FBS 10% FBS
10 μM
RA
10 μM
RA
1 μM RA
1 μM hApoD1 μMRA
1 μM
RA
0% FBS
1 μM RA
1 μM hApoD
0% FBS
1 μM RA
1 μM NLaz
Fig S6.
Quantification of neurite length upon retinoic acid induced differentiation of 
SH-SY5Y (A) or M17 (B) neuronal cell lines. No changes are observed in 
the length of neurites between treatments. Kruskal-Wallis one-way ANOVA 
on Ranks (p>0.05).
Table 1. Comparison of apparent KD values for the binding of various 
ligands to Lipocalins (average value ±  S.D.). 
 
Protein Ligand KD (µM) n 
hApoD 
All-trans-Retinoic Acid 4.0±2.6 8 
Retinol 0.2±0.1 7 
Cholesterol n/d 3 
Ergosterol n/d 4 
Palmitoyl Sphingomyelin 1.3±0.5 6 
Palmitic Acid 3.3±0.6 8 
PLPE n/d 3 
β-Estradiol n/d 7 
2-Arachidonyl-Glycerol n/d 3 
Anandamide 1.6±1.3 10 
NLaz 
All-trans-Retinoic Acid 1.4±1.6 9 
Retinol 0.9±1.2 10 
Cholesterol 3.5±0.5 4 
Ergosterol 2.7±0.7 6 
Palmitoyl Sphingomyelin 4.6±0.2 8 
Palmitic Acid 4.7±0.2 6 
Arachidic Acid 4.5±0.7 3 
PLPE n/d 8 
7(Z)-Tricosene 4.5±0.6 6 
7(Z),(11)-Heptacosadiene n/d 6 
11-cis-Vaccenil-Acetate n/d 5 
20-Hydroxyecdysone n/d 3 
Lazarillo (S2) 
All-trans-Retinoic Acid 3.0±1.1 8 
Retinol 2.1±0.6 5 
Cholesterol n/d 3 
Ergosterol 2.0±0.1 7 
Palmitoyl Sphingomyelin 2.7±0.2 7 
PLPE n/d 5 
Lazarillo (E.coli) All-trans-Retinoic Acid 2.6±1.8 3 Palmitoyl Sphingomyelin 3.0±2.6 3 
α1-microglobulin Retinol 1.4±0.1 4 Palmitoyl Sphingomyelin n/d 3 
 n = number of independent ligand-titration experiments. 
